Paper Report for: Deng_2019_Pak.J.Pharm.Sci_32_2091
Reference
Title: Design, synthesis and biological Evaluation of Dual acetyl cholinesterase and beta-secretase inhibitors in treatment for alzheimer's Disease Deng Y, Jiang Y, Zhao X, Wang J Ref: Pak J Pharm Sci, 32:2091, 2019 : PubMed
With the recent research advances in molecular biology and technology multiple credible hypotheses about the progress of Alzheimer's disease (AD) have been proposed, among which the amyloid and cholinergic hypotheses are commonly used to develop reliable therapeutic agents. The multitarget-directed ligand (MTDL) approach was taken in this work to develop muilti-functional agents, which can mainly serve as dual beta-secretase (BACE 1) and Acetylcholinesterase (AChE) inhibitors. Series of new compounds were designed, synthesized and evaluated in this work, from which we identified 2-((4-(1,3-dioxoisoindolin-2-yl)benzyl)amino)-2-oxoethyl-2-(4-methoxyphenyl)aceta te (1h) as a new dual cholinesterase and beta-secretase inhibitor without toxicity.
        
Related information
Citations formats
Deng Y, Jiang Y, Zhao X, Wang J (2019) Design, synthesis and biological Evaluation of Dual acetyl cholinesterase and beta-secretase inhibitors in treatment for alzheimer's Disease Pak J Pharm Sci32: 2091-2098
Deng Y, Jiang Y, Zhao X, Wang J (2019) Pak J Pharm Sci32: 2091-2098